Dipti Amin is Director at Lineage Cell Therapeutics, Inc. (LCTX). They have made 1 open-market trade across 1 company since 2022, most recently 2022-03-28.
CIK 0001856708
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $114K since 2022, never a sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| LCTX | 35,000 | $35K |
Shares reported on the most recent Form 4, priced at the 2022-03-29 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| LCTX | BUY | 2022-03-28 | 2022-03-29 | $1.63 | $114K | -10.5% | -19.6% | -3.3% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.